---
title: "Nomura Cuts JD HEALTH  TP to HKD51; 4Q Revenue Outlook Weakens but Margin Expansion May Persist"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306088883.md"
description: "Nomura cut JD Health's target price to HKD51 and maintained a 'Buy' rating, citing mixed Q3 results and weakened revenue outlook. While Q3 revenue grew 17% YoY, margin expansion was limited by higher marketing costs. The broker lowered full-year 2026 revenue growth guidance due to regulatory impacts on nutritional brands but expects Q4 profit expansion to resume. Revenue forecasts for 2026-2027 were slightly reduced, though the 2027 adjusted net profit forecast was raised."
datetime: "2026-11-19T08:51:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306088883.md)
  - [en](https://longbridge.com/en/news/306088883.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306088883.md)
generator: "portal-rs"
---

# Nomura Cuts JD HEALTH  TP to HKD51; 4Q Revenue Outlook Weakens but Margin Expansion May Persist

Nomura said in a research report that JD HEALTH (06618.HK) -2.440 (-6.999%) Short selling $304.93M; Ratio 32.620% 's third-quarter results were mixed. Revenue rose 17% YoY to RMB20 billion, 1% above the broker's forecast, mainly driven by a rebound in nutritional product sales. Non-IFRS operating profit increased 14% YoY to RMB1.6 billion, 2% below the broker's forecast, while operating margin edged down 0.2 ppts YoY to 7.9%, mainly due to higher marketing expenses.

Management lowered its full-year 2026 revenue growth guidance from high-teens to mid-teens, mainly due to one-off impacts from regulatory reviews and recalls involving certain key nutritional brands. The broker expects fourth-quarter revenue growth to slow to around 10%, but believes the third-quarter contraction in operating margin was temporary and that fourth-quarter non-IFRS operating profit may resume YoY expansion.

The broker lowered its 2026 and 2027 revenue forecasts for JD HEALTH by 2% and 3%, respectively, but raised its 2027 adjusted net profit forecast by 2%. It maintained the "Buy" rating and cut the TP from HKD60 to HKD51, equivalent to 10x adjusted P/E for 2027.(da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-19 16:25.)

### Related Stocks

- [06618.HK](https://longbridge.com/en/quote/06618.HK.md)
- [86618.HK](https://longbridge.com/en/quote/86618.HK.md)

## Related News & Research

- [JD Health Trustee Purchases Shares for Post-IPO Award Scheme](https://longbridge.com/en/news/306036144.md)
- [BofAS Cuts JD HEALTH TP to HKD57; 1H Earnings Beat](https://longbridge.com/en/news/295915379.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**